Safety and efficacy of intracapsular tranilast microspheres in experimental posterior capsule opacification

Journal of Cataract and Refractive Surgery

Volumn 33, Issue 12, 2007, Pages 2122-2128

  Wang, Man ^a   Zhang, Jin Jun ^a   Jackson, Timothy L ^a   Sun, Xinghuai ^a   Wu, Wei ^a   Marshall, John ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TRANILAST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATARACT; CLINICAL EXAMINATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PHACOEMULSIFICATION; PRIORITY JOURNAL; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE;

ANIMALS; ANTHRANILIC ACIDS; ANTI-ALLERGIC AGENTS; CATARACT; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INJECTIONS; LENS CAPSULE, CRYSTALLINE; MALE; MICROSPHERES; PHACOEMULSIFICATION; POSTOPERATIVE COMPLICATIONS; RABBITS; TIME FACTORS; TREATMENT OUTCOME;

EID: 36549001858     PISSN: 08863350     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcrs.2007.07.041     Document Type: Article

References (39)

1. Apple D.J., Auffarth G.U., Peng Q., and Visessook N. Foldable Intraocular Lenses; Evolution, Clinicopathologic Correlations, and Complications (2000), Slack, Inc, Thorofare, NJ
2. Apple D.J., Ram J., Foster A., and Peng Q. Elimination of cataract blindness: a global perspective entering the new millennium. Surv Ophthalmol 45 suppl 1 (2000) S70-S99
3. Nishi O. Posterior capsule opacification. Part 1: experimental investigations. J Cataract Refract Surg 25 (1999) 106-117
4. Werner L., Apple D.J., and Pandey S.K. Postoperative proliferation of anterior and equatorial lens epithelial cells. In: Buratto L., Osher R.H., and Masket S. (Eds). Cataract Surgery in Complicated Cases (2000), Slack, Thorofare, NJ 399-417
5. Apple D.J., Peng Q., Visessook N., et al. Eradication of posterior capsule opacification; documentation of a marked decrease in Nd:YAG laser posterior capsulotomy rates noted in an analysis of 5416 pseudophakic human eyes obtained postmortem. Ophthalmology 108 (2001) 505-518
6. Wilson M.E., Pandey S.K., Werner L., et al. Pediatric cataract surgery: current techniques, complications and management. In: Agarwal S., Agarwal A., Sachdev M.S., et al. (Eds). Phacoemulsification, Laser Cataract Surgery and Foldable IOLs. 2nd ed (2000), India, Jaypee Brothers, New Delhi 369-388
7. Magno B.V., Datiles M.B., Lasa M.S.M., et al. Evaluation of visual function following neodymium:YAG laser posterior capsulotomy. Ophthalmology 104 (1997) 1287-1293
8. Haus C.M., and Galand A.L. Mitomycin against posterior capsular opacification: an experimental study in rabbits. Br J Ophthalmol 80 (1996) 1087-1091
9. Ismail M.M., Alió J.L., and Ruiz Moreno J.M. Prevention of secondary cataract by antimitotic drugs: experimental study. Ophthalmic Res 28 (1996) 64-69
10. Nishi O., Nishi K., Mano C., et al. Inhibition of migrating lens epithelial cells by blocking the adhesion molecule integrin: a preliminary report. J Cataract Refract Surg 23 (1997) 860-865
11. Meacock W.R., Spalton D.J., Hollick E.J., et al. Double-masked prospective ocular safety study of a lens epithelial cell antibody to prevent posterior capsule opacification. J Cataract Refract Surg 26 (2000) 716-721
12. Behar-Cohen F.F., David T., Buechler Y., et al. Cytotoxic effects of FGF2-saporin on bovine epithelial lens cells in vitro. Invest Ophthalmol Vis Sci 36 (1995) 2425-2433
13. Nishi O., Nishi K., Saitoh I., and Sakanishi K. Inhibition of migrating lens epithelial cells by sustained release of ethylenediaminetetraacetic acid. J Cataract Refract Surg 22 (1996) 863-868
14. Clark D.S., Emery J.M., and Munsel M.F. Inhibition of posterior capsule opacification with an immunotoxin specific for lens epithelial cells: 24 month clinical results. J Cataract Refract Surg 24 (1998) 1614-1620
15. Inan U., Öztürk F., Kaynak S., et al. Prevention of posterior capsule opacification by intraoperative single-dose pharmacologic agents. J Cataract Refract Surg 27 (2001) 1079-1087
16. Legler U.F.C., Apple D.J., Assia E.I., et al. Inhibition of posterior capsule opacification: the effect of colchicine in a sustained drug delivery system. J Cataract Refract Surg 19 (1993) 462-470
17. Tetz M.R., Ries M.W., Lucas C., et al. Inhibition of posterior capsule opacification by an intraocular-lens-bound sustained drug delivery system: an experimental animal study and literature review. J Cataract Refract Surg 22 (1996) 1070-1078
18. Pandey S.K., Cochener B., Apple D.J., et al. Intracapsular ring sustained 5-fluorouracil delivery system for prevention of posterior capsule opacification in rabbits: a histological study. J Cataract Refract Surg 28 (2002) 139-148
19. Hiratochi M., Takamoto M., Tatemichi S., and Sugane K. Inhibition of interleukin 5 production with no influence on interleukin 4 production by an anti-allergic drug, tranilast, in Toxocara canis-infected mice. Int J Immunopharmacol 22 (2000) 463-471
20. 2 from human monocytes-macrophages. Jpn J Pharmacol 60 (1992) 85-90. Available at: http://www.journalarchive.jst.go.jp/jnlpdf.php?cdjournal=jphs1951&cd vol=60&noissue=2&startpage=85&lang=en&from=jnltoc Accessed July 30, 2007
21. Koyama S., Takagi H., Otani A., et al. Tranilast inhibits protein kinase C-dependent signalling pathway linked to angiogenic activities and gene expression of retinal microcapillary endothelial cells. Br J Pharmacol 127 (1999) 537-545. http://www.nature.com/bjp/journal/v127/n2/pdf/0702564a.pdf Accessed July 30, 2007
22. Isaji M., Miyata H., Ajisawa Y., et al. Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo. Br J Pharmacol 122 (1997) 1061-1066. http://www.nature.com/bjp/journal/v122/n6/pdf/0701493a.pdf Accessed July 30, 2007
23. Isaji M., Miyata H., Ajisawa Y., and Yoshimura N. Inhibition by tranilast of vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF)-induced increase in vascular permeability in rats. Life Science 63 4 (1998) PL71-PL74
24. Platten M., Wild-Bode C., Wick W., et al. N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-β release and reduces migration and invasiveness of human malignant glioma cells. Int J Cancer 93 (2001) 53-61
25. Nagata R., Arimura S., Samejima H., et al. [Frequent eye irritation study of a short-term and subacute toxicity of tranilast (N-5′) ophthalmic solution in rabbits]. [Japanese] Kiso-to-Rinsho 26 (1992) 3463-3469
26. Kogure F., Ishizaki M., and Saiga T. Long-term clinical study of tranilast ophthalmic solution on vernal conjunctivitis. J Clin Ther Med 9 (1993) 429-441
27. National Basic Drugs Leading Group. National Basic Drugs, published by People Health Publisher, China Public Health Bureau, August 1999; 680-681
28. Tobari I., Iwaki Y., Miyake K., et al. Effect of tranilast eyedrops in preventing posterior capsule opacification: preliminary report. J Cataract Refract Surg 25 (1999) 1394-1399
29. Tani E., Katakami C., and Negi A. Effect of various eye drops on corneal wound healing after superficial keratectomy in rabbits. Jpn J Ophthalmol 46 (2002) 488-495
30. Ito S., Sakamoto T., Tahara Y., et al. The effect of tranilast on experimental proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 237 (1999) 691-696
31. Takehana Y., Kurokawa T., Kitamura T., et al. Suppression of laser-induced choroidal neovascularization by oral tranilast in the rat. Invest Ophthalmol Vis Sci 40 (1999) 459-466
32. Geroski D.H., and Edelhauser H.F. Drug delivery for posterior segment eye disease. Invest Ophthalmol Vis Sci 41 (2000) 961-964
33. Herrero-Vanrell R., and Refojo M.F. Biodegradable microspheres for vitreoretinal drug delivery. Adv Drug Deliv Rev 52 (2001) 5-16
34. Kumar M.T., Pandit J.K., and Balasubramaniam J. Novel therapeutic approaches for uveitis and retinitis. J Pharm Pharm Sci 4 (2001) 248-254. Available at: http://www.ualberta.ca/∼csps/JPPS4(3)/J.Balasubramaniam/retinitis.pd f Accessed July 30, 2007
35. Sattari S., and Jamali F. High performance liquid chromatographic determination of cyclooxygenase II inhibitor rofecoxib in rats and human plasma. J Pharm Pharm Sci 3 (2000) 312-316. Available at: http://www.ualberta.ca/∼csps/JPPS3(3)/F.Jamali/Jamali-Rofecoxib.pdf Accessed July 30, 2007
36. Bohlooli S., Keyhanfar F., and Mamoudian M. High performance liquid chromatography of mebudipine: application to pharmacokinetic study. J Pharm Pharm Sci 4 (2001) 244-247. Available at: http://www.ualberta.ca/∼csps/JPPS4(3)/M.Mahmoudian(2)/mebudipine.pdf Accessed July 30, 2007
37. Friedman D.S., Duncan D.D., Munoz B., et al. Digital image capture and automated analysis of posterior capsular opacification. Invest Ophthalmol Vis Sci 40 (1999) 1715-1726
38. Miyazawa Y., Iwaki Y., Yataka M., and Tobari I. [Effect of different concentrations of tranilast on posterior capsule opacification]. [Japanese] Nippon Ganka Gakkai Zasshi 105 (2001) 442-446
39. Le Bourlais C., Acar L., Zia H., et al. Ophthalmic drug delivery systems-recent advances. Prog Retin Eye Res 17 (1998) 33-58